O	0	4	Host	Host	NN	B-NP
O	4	5	-	-	HYPH	B-PP
O	5	12	derived	derive	VBN	B-NP
O	13	25	angiopoietin	angiopoietin	NN	I-NP
O	25	26	-	-	HYPH	O
O	26	27	2	2	CD	B-NP
O	28	35	affects	affect	VBZ	B-VP
O	36	41	early	early	JJ	B-NP
O	42	48	stages	stage	NNS	I-NP
O	49	51	of	of	IN	B-PP
B-Cancer	52	57	tumor	tumor	NN	B-NP
O	58	69	development	development	NN	I-NP
O	70	73	and	and	CC	O
B-Multi-tissue_structure	74	80	vessel	vessel	NN	B-NP
O	81	91	maturation	maturation	NN	I-NP
O	92	95	but	but	CC	O
O	96	98	is	be	VBZ	B-VP
O	99	110	dispensable	dispensable	JJ	B-ADJP
O	111	114	for	for	IN	B-PP
O	115	120	later	later	JJ	B-NP
O	121	127	stages	stage	NNS	I-NP
O	128	130	of	of	IN	B-PP
B-Cancer	131	136	tumor	tumor	NN	B-NP
O	137	143	growth	growth	NN	I-NP
O	143	144	.	.	.	O

O	145	148	The	The	DT	B-NP
O	149	161	angiopoietin	angiopoietin	NN	I-NP
O	161	162	/	/	SYM	I-NP
O	162	166	Tie2	Tie2	NN	I-NP
O	167	173	system	system	NN	I-NP
O	174	177	has	have	VBZ	B-VP
O	178	182	been	be	VBN	I-VP
O	183	193	identified	identify	VBN	I-VP
O	194	196	as	as	IN	B-PP
O	197	200	the	the	DT	B-NP
O	201	207	second	second	JJ	I-NP
B-Multi-tissue_structure	208	216	vascular	vascular	JJ	I-NP
O	216	217	-	-	HYPH	I-NP
O	217	225	specific	specific	JJ	I-NP
O	226	234	receptor	receptor	NN	I-NP
O	235	243	tyrosine	tyrosine	NN	I-NP
O	244	250	kinase	kinase	NN	I-NP
O	251	257	system	system	NN	I-NP
O	258	269	controlling	control	VBG	B-VP
B-Multi-tissue_structure	270	276	vessel	vessel	NN	B-NP
O	277	285	assembly	assembly	NN	I-NP
O	285	286	,	,	,	O
O	287	297	maturation	maturation	NN	B-NP
O	297	298	,	,	,	O
O	299	302	and	and	CC	O
O	303	313	quiescence	quiescence	NN	B-NP
O	313	314	.	.	.	O

O	315	327	Angiopoietin	Angiopoietin	NN	B-NP
O	327	328	-	-	HYPH	O
O	328	329	2	2	CD	B-NP
O	330	331	(	(	(	O
O	331	334	Ang	Ang	NN	B-NP
O	334	335	-	-	HYPH	B-NP
O	335	336	2	2	CD	I-NP
O	336	337	)	)	)	O
O	338	340	is	be	VBZ	B-VP
O	341	352	prominently	prominently	RB	B-ADVP
O	353	355	up	up	RB	B-ADVP
O	355	356	-	-	HYPH	B-NP
O	356	365	regulated	regulate	VBN	B-VP
O	366	368	in	in	IN	B-PP
O	369	372	the	the	DT	B-NP
O	373	377	host	host	NN	I-NP
O	377	378	-	-	HYPH	B-VP
O	378	385	derived	derive	VBN	B-NP
B-Multi-tissue_structure	386	397	vasculature	vasculature	NN	I-NP
O	398	400	of	of	IN	B-PP
O	401	405	most	most	JJS	B-NP
B-Cancer	406	412	tumors	tumor	NNS	I-NP
O	412	413	,	,	,	O
O	414	420	making	make	VBG	B-VP
O	421	423	it	it	PRP	B-NP
O	424	426	an	an	DT	B-NP
O	427	437	attractive	attractive	JJ	I-NP
O	438	447	candidate	candidate	NN	I-NP
O	448	451	for	for	IN	B-PP
O	452	466	antiangiogenic	antiangiogenic	JJ	B-NP
O	467	479	intervention	intervention	NN	I-NP
O	479	480	.	.	.	O

O	481	484	Yet	Yet	RB	B-ADVP
O	484	485	,	,	,	O
O	486	489	the	the	DT	B-NP
O	490	493	net	net	JJ	I-NP
O	494	501	outcome	outcome	NN	I-NP
O	502	504	of	of	IN	B-PP
O	505	508	Ang	Ang	NN	B-NP
O	508	509	-	-	HYPH	O
O	509	510	2	2	CD	B-NP
O	511	520	functions	function	NNS	I-NP
O	521	523	on	on	IN	B-PP
B-Cancer	524	529	tumor	tumor	NN	B-NP
O	530	542	angiogenesis	angiogenesis	NN	I-NP
O	543	545	is	be	VBZ	B-VP
O	546	554	believed	believe	VBN	I-VP
O	555	557	to	to	TO	I-VP
O	558	560	be	be	VB	I-VP
O	561	571	contextual	contextual	JJ	B-ADJP
O	572	581	depending	depend	VBG	B-PP
O	582	584	on	on	IN	B-PP
O	585	588	the	the	DT	B-NP
O	589	594	local	local	JJ	I-NP
O	595	603	cytokine	cytokine	NN	I-NP
O	604	610	milieu	milieu	NN	I-NP
O	610	611	.	.	.	O

O	612	627	Correspondingly	Correspondingly	RB	B-ADVP
O	627	628	,	,	,	O
O	629	632	Ang	Ang	NNP	B-NP
O	632	633	-	-	HYPH	B-NP
O	633	634	2	2	CD	I-NP
O	635	647	manipulatory	manipulatory	JJ	I-NP
O	648	657	therapies	therapy	NNS	I-NP
O	658	662	have	have	VBP	B-VP
O	663	667	been	be	VBN	I-VP
O	668	673	shown	show	VBN	I-VP
O	674	676	to	to	TO	I-VP
O	677	682	exert	exert	VB	I-VP
O	683	697	protumorigenic	protumorigenic	JJ	O
O	698	700	as	as	RB	B-CONJP
O	701	705	well	well	RB	I-CONJP
O	706	708	as	as	IN	I-CONJP
O	709	724	antitumorigenic	antitumorigenic	JJ	B-NP
O	725	732	effects	effect	NNS	I-NP
O	732	733	.	.	.	O

O	734	736	To	To	TO	B-VP
O	737	744	clarify	clarify	VB	I-VP
O	745	748	the	the	DT	B-NP
O	749	753	role	role	NN	I-NP
O	754	756	of	of	IN	B-PP
O	757	760	Ang	Ang	NN	B-NP
O	760	761	-	-	HYPH	B-NP
O	761	762	2	2	CD	I-NP
O	763	766	for	for	IN	B-PP
O	767	779	angiogenesis	angiogenesis	NN	B-NP
O	780	783	and	and	CC	I-NP
B-Cancer	784	789	tumor	tumor	NN	I-NP
O	790	796	growth	growth	NN	I-NP
O	797	799	in	in	IN	B-PP
O	800	801	a	a	DT	B-NP
O	802	810	definite	definite	JJ	I-NP
O	811	818	genetic	genetic	JJ	I-NP
O	819	831	experimental	experimental	JJ	I-NP
O	832	839	setting	setting	NN	I-NP
O	839	840	,	,	,	O
O	841	844	the	the	DT	B-NP
O	845	852	present	present	JJ	I-NP
O	853	858	study	study	NN	I-NP
O	859	862	was	be	VBD	B-VP
O	863	868	aimed	aim	VBN	I-VP
O	869	871	at	at	IN	B-PP
O	872	885	comparatively	comparatively	RB	B-VP
O	886	894	studying	study	VBG	I-VP
O	895	898	the	the	DT	B-NP
O	899	905	growth	growth	NN	I-NP
O	906	908	of	of	IN	B-PP
O	909	918	different	different	JJ	B-NP
B-Cancer	919	925	tumors	tumor	NNS	I-NP
O	926	928	in	in	IN	B-PP
O	929	933	wild	wild	JJ	B-NP
O	933	934	-	-	HYPH	I-NP
O	934	938	type	type	NN	I-NP
O	939	942	and	and	CC	I-NP
O	943	946	Ang	Ang	NN	I-NP
O	946	947	-	-	HYPH	B-NP
O	947	948	2	2	CD	I-NP
O	948	949	-	-	HYPH	I-NP
O	949	958	deficient	deficient	JJ	I-NP
O	959	963	mice	mouse	NNS	I-NP
O	963	964	.	.	.	O

B-Cancer	965	970	Lewis	Lewis	NNP	B-NP
I-Cancer	971	975	lung	lung	NN	I-NP
I-Cancer	976	986	carcinomas	carcinoma	NNS	I-NP
O	986	987	,	,	,	O
B-Cancer	988	990	MT	MT	NN	B-NP
I-Cancer	990	991	-	-	HYPH	I-NP
I-Cancer	991	994	ret	ret	NN	I-NP
I-Cancer	995	1004	melanomas	melanoma	NNS	I-NP
O	1004	1005	,	,	,	O
O	1006	1009	and	and	CC	O
B-Cancer	1010	1016	B16F10	B16F10	NN	B-NP
I-Cancer	1017	1026	melanomas	melanoma	NNS	I-NP
O	1027	1030	all	all	DT	O
O	1031	1035	grew	grow	VBD	B-VP
O	1036	1042	slower	slow	JJR	B-ADJP
O	1043	1045	in	in	IN	B-PP
O	1046	1049	Ang	Ang	NNP	B-NP
O	1049	1050	-	-	HYPH	B-NP
O	1050	1051	2	2	CD	I-NP
O	1051	1052	-	-	HYPH	I-NP
O	1052	1061	deficient	deficient	JJ	I-NP
O	1062	1066	mice	mouse	NNS	I-NP
O	1066	1067	.	.	.	O

O	1068	1071	Yet	Yet	RB	B-ADVP
O	1071	1072	,	,	,	O
B-Cancer	1073	1078	tumor	tumor	NN	B-NP
O	1079	1085	growth	growth	NN	I-NP
O	1086	1088	in	in	IN	B-PP
O	1089	1093	wild	wild	JJ	B-NP
O	1093	1094	-	-	HYPH	I-NP
O	1094	1098	type	type	NN	I-NP
O	1099	1102	and	and	CC	I-NP
O	1103	1106	Ang	Ang	NN	I-NP
O	1106	1107	-	-	HYPH	B-NP
O	1107	1108	2	2	CD	I-NP
O	1108	1109	-	-	HYPH	I-NP
O	1109	1118	deficient	deficient	JJ	I-NP
O	1119	1123	mice	mouse	NNS	I-NP
O	1124	1135	dissociated	dissociate	VBN	B-VP
O	1136	1142	during	during	IN	B-PP
O	1143	1148	early	early	JJ	B-NP
O	1149	1155	stages	stage	NNS	I-NP
O	1156	1158	of	of	IN	B-PP
B-Cancer	1159	1164	tumor	tumor	NN	B-NP
O	1165	1176	development	development	NN	I-NP
O	1176	1177	,	,	,	O
O	1178	1185	whereas	whereas	IN	O
B-Cancer	1186	1191	tumor	tumor	NN	B-NP
O	1192	1198	growth	growth	NN	I-NP
O	1199	1204	rates	rate	NNS	I-NP
O	1205	1211	during	during	IN	B-PP
O	1212	1217	later	later	JJ	B-NP
O	1218	1224	stages	stage	NNS	I-NP
O	1225	1227	of	of	IN	B-PP
B-Cancer	1228	1235	primary	primary	JJ	B-NP
I-Cancer	1236	1241	tumor	tumor	NN	I-NP
O	1242	1253	progression	progression	NN	I-NP
O	1254	1258	were	be	VBD	B-VP
O	1259	1266	similar	similar	JJ	B-ADJP
O	1266	1267	.	.	.	O

O	1268	1276	Analysis	Analysis	NN	B-NP
O	1277	1279	of	of	IN	B-PP
O	1280	1283	the	the	DT	B-NP
B-Multi-tissue_structure	1284	1296	intratumoral	intratumoral	JJ	I-NP
I-Multi-tissue_structure	1297	1305	vascular	vascular	JJ	I-NP
I-Multi-tissue_structure	1306	1318	architecture	architecture	NN	I-NP
O	1319	1327	revealed	reveal	VBD	B-VP
O	1328	1330	no	no	DT	B-NP
O	1331	1336	major	major	JJ	I-NP
O	1337	1348	differences	difference	NNS	I-NP
O	1349	1351	in	in	IN	B-PP
B-Tissue	1352	1363	microvessel	microvessel	NN	B-NP
O	1364	1371	density	density	NN	I-NP
O	1372	1375	and	and	CC	I-NP
O	1376	1385	perfusion	perfusion	NN	I-NP
O	1386	1401	characteristics	characteristic	NNS	I-NP
O	1401	1402	.	.	.	O

O	1403	1410	However	However	RB	B-ADVP
O	1410	1411	,	,	,	O
O	1412	1421	diameters	diameter	NNS	B-NP
O	1422	1424	of	of	IN	B-PP
B-Tissue	1425	1437	intratumoral	intratumoral	JJ	B-NP
I-Tissue	1438	1450	microvessels	microvessel	NNS	I-NP
O	1451	1455	were	be	VBD	B-VP
O	1456	1463	smaller	small	JJR	B-ADJP
O	1464	1466	in	in	IN	B-PP
B-Cancer	1467	1473	tumors	tumor	NNS	B-NP
O	1474	1479	grown	grow	VBN	B-VP
O	1480	1482	in	in	IN	B-PP
O	1483	1486	Ang	Ang	NNP	B-NP
O	1486	1487	-	-	HYPH	B-NP
O	1487	1488	2	2	CD	I-NP
O	1488	1489	-	-	HYPH	I-NP
O	1489	1498	deficient	deficient	JJ	I-NP
O	1499	1503	mice	mouse	NNS	I-NP
O	1503	1504	,	,	,	O
O	1505	1508	and	and	CC	O
O	1509	1512	the	the	DT	B-NP
B-Multi-tissue_structure	1513	1524	vasculature	vasculature	NN	I-NP
O	1525	1528	had	have	VBD	B-VP
O	1529	1531	an	an	DT	B-NP
O	1532	1539	altered	altered	JJ	I-NP
O	1540	1547	pattern	pattern	NN	I-NP
O	1548	1550	of	of	IN	B-PP
B-Cell	1551	1559	pericyte	pericyte	NN	B-NP
O	1560	1571	recruitment	recruitment	NN	I-NP
O	1572	1575	and	and	CC	I-NP
O	1576	1586	maturation	maturation	NN	I-NP
O	1586	1587	.	.	.	O

B-Tissue	1588	1591	Ang	Ang	NN	B-NP
I-Tissue	1591	1592	-	-	HYPH	B-NP
I-Tissue	1592	1593	2	2	CD	I-NP
I-Tissue	1593	1594	-	-	HYPH	I-NP
I-Tissue	1594	1603	deficient	deficient	JJ	I-NP
I-Tissue	1604	1609	tumor	tumor	NN	I-NP
I-Tissue	1610	1617	vessels	vessel	NNS	I-NP
O	1618	1621	had	have	VBD	B-VP
O	1622	1628	higher	high	JJR	B-NP
B-Cell	1629	1637	pericyte	pericyte	NN	I-NP
O	1638	1646	coverage	coverage	NN	I-NP
O	1647	1654	indices	index	NNS	I-NP
O	1654	1655	.	.	.	O

O	1656	1665	Recruited	Recruit	VBN	B-NP
B-Cell	1666	1675	pericytes	pericyte	NNS	I-NP
O	1676	1680	were	be	VBD	B-VP
O	1681	1687	desmin	desmin	NN	B-NP
O	1688	1691	and	and	CC	I-NP
O	1692	1695	NG2	NG2	NN	I-NP
O	1696	1704	positive	positive	JJ	B-ADJP
O	1705	1708	and	and	CC	O
O	1709	1722	predominately	predominately	RB	B-ADJP
O	1723	1728	alpha	alpha	SYM	I-ADJP
O	1728	1729	-	-	HYPH	B-NP
O	1729	1735	smooth	smooth	JJ	I-NP
O	1736	1742	muscle	muscle	NN	I-NP
O	1743	1748	actin	actin	NN	I-NP
O	1749	1757	negative	negative	JJ	B-ADJP
O	1757	1758	,	,	,	O
O	1759	1769	indicative	indicative	JJ	B-ADJP
O	1770	1772	of	of	IN	B-PP
O	1773	1774	a	a	DT	B-NP
O	1775	1779	more	more	RBR	I-NP
O	1780	1786	mature	mature	JJ	I-NP
B-Cell	1787	1795	pericyte	pericyte	NN	I-NP
O	1796	1805	phenotype	phenotype	NN	I-NP
O	1805	1806	.	.	.	O

O	1807	1819	Collectively	Collectively	RB	B-ADVP
O	1819	1820	,	,	,	O
O	1821	1824	the	the	DT	B-NP
O	1825	1836	experiments	experiment	NNS	I-NP
O	1837	1843	define	define	VBP	B-VP
O	1844	1847	the	the	DT	B-NP
O	1848	1852	role	role	NN	I-NP
O	1853	1855	of	of	IN	B-PP
O	1856	1859	Ang	Ang	NN	B-NP
O	1859	1860	-	-	HYPH	O
O	1860	1861	2	2	CD	B-NP
O	1862	1868	during	during	IN	B-PP
B-Cancer	1869	1874	tumor	tumor	NN	B-NP
O	1875	1887	angiogenesis	angiogenesis	NN	I-NP
O	1888	1891	and	and	CC	O
O	1892	1901	establish	establish	VB	B-VP
O	1902	1903	a	a	DT	B-NP
O	1904	1910	better	good	JJR	I-NP
O	1911	1920	rationale	rationale	NN	I-NP
O	1921	1924	for	for	IN	B-PP
O	1925	1936	combination	combination	NN	B-NP
O	1937	1946	therapies	therapy	NNS	I-NP
O	1947	1956	involving	involve	VBG	B-VP
O	1957	1960	Ang	Ang	NN	B-NP
O	1960	1961	-	-	HYPH	B-NP
O	1961	1962	2	2	CD	I-NP
O	1963	1975	manipulatory	manipulatory	JJ	I-NP
O	1976	1985	therapies	therapy	NNS	I-NP
O	1985	1986	.	.	.	O

